From: Outsider Club <ww-eletter@angelnexus.com>
Date: Sat, Dec 27, 2014 at 2:07 PM
Subject: History Repeats in Four Days...
To: pascal.alter@gmail.com
Having trouble viewing this issue? Click here. Dear Reader, 72 years ago, penicillin changed the world. It eliminated infectious diseases... It gave the Allies a decisive advantage in World War II... And it expanded human life expectancy by as much as 25 years. Now, there's a new blockbuster on the market... One potentially as life changing as penicillin. It's promising to end all pain — naturally and safely. And just like penicillin, it will not only kick off a new wave of pharmaceutical giants... But it will also return early investors astronomical gains in the process. What kind of returns are we talking about here? Well, penicillin led to the rise of drug companies like Pfizer, Merck, and Bristol-Myers Squibb. And if you had bought into these companies early on, you could have seen nothing short of earth-shattering gains like 1,640%. Enough to turn every $100 invested into $1,640,000. This time around is NO different. History is repeating itself. And if you take action now — before the FDA approves this new blockbuster on December 31 — you could position yourself for the greatest profit story in history... one that could make you rich regardless of your initial investment. Click here to get started now. Godspeed, Jimmy Mengel This email was sent to pascal.alter@gmail.com . You can manage your subscription and get our privacy policy here. Outsider Club, Copyright © 2014, Angel Publishing LLC, 111 Market Place #720, Baltimore, MD 21202. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Outsider Club does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law. Please note: It is not our intention to send email to anyone who doesn't want it. (.....) |
Brak komentarzy:
Prześlij komentarz